Wednesday, June 1, 2011

Sangamo BioSciences new ZFP Therapeutics® to treat Hemophilia?

This intrigues me although I have almost no idea what they are talking about.

"Therapeutic areas included ZFN-based approaches to infectious diseases such as HIV/AIDS and monogenic diseases such as hemophilia, ADA-SCID, retinal neurodegeneration and epidermolysis bullosa. Positive preclinical data were also presented from studies of Sangamo's ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene in an animal model of stroke."

No comments:

Related Posts Plugin for WordPress, Blogger...